Petit T - Search Results

1

Complete remission seven years after treatment for metastatic malignant melanoma.

Petit T, Borel C, Rixe O, Avril MF, Monnier A, Giroux B, Weil M, Khayat D. Petit T, et al. Cancer. 1996 Mar 1;77(5):900-2. Cancer. 1996. PMID: 8608481 Clinical Trial.

2

Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.

Rixe O, Borel C, Paraiso D, Benhammouda A, Petit T, Antoine E, Bizzari JP, Auclerc G, Soubrane C, Weil M, et al. Rixe O, et al. Among authors: petit t. Melanoma Res. 1995 Dec;5(6):419-24. doi: 10.1097/00008390-199512000-00005. Melanoma Res. 1995. PMID: 8589616 Clinical Trial.

3

A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer.

Rixe O, Coeffic D, Orcel B, Maitre B, Borel C, Benhammouda A, Petit T, Khayat D, Derenne JP. Rixe O, et al. Among authors: petit t. Am J Clin Oncol. 1997 Apr;20(2):128-31. doi: 10.1097/00000421-199704000-00004. Am J Clin Oncol. 1997. PMID: 9124184 Clinical Trial.

4

Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.

Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegelé P. Petit T, et al. Clin Cancer Res. 2001 Jun;7(6):1577-81. Clin Cancer Res. 2001. PMID: 11410493

5

Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer.

Petit T, Borel C, Theobald S, Serin D, Rodier JF, Prevot G, Brettes JP, Klein T. Petit T, et al. Ann Surg Oncol. 2003 May;10(4):369-75. doi: 10.1245/aso.2003.07.015. Ann Surg Oncol. 2003. PMID: 12734084 Clinical Trial.

6

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M, Ghnassia JP. Petit T, et al. Eur J Cancer. 2004 Jan;40(2):205-11. doi: 10.1016/s0959-8049(03)00675-0. Eur J Cancer. 2004. PMID: 14728934

7

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P. Dieras V, et al. Among authors: petit t. Ann Oncol. 2002 Feb;13(2):258-66. doi: 10.1093/annonc/mdf018. Ann Oncol. 2002. PMID: 11886003 Free article. Clinical Trial.

8

Complete remission seven years after treatment for metastatic malignant melanoma.

Petit T, Janser JC, Petit JC. Petit T, et al. Among authors: petit jc. Cancer. 1996 Aug 1;78(3):571. doi: 10.1002/(SICI)1097-0142(19960801)78:3<571::AID-CNCR34>3.0.CO;2-U. Cancer. 1996. PMID: 8697410 No abstract available.

9

Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma.

Petit T, Georges C, Jung GM, Borel C, Bronner G, Flesch H, Massard G, Velten M, Haegele P, Schraub S. Petit T, et al. Ann Oncol. 2001 May;12(5):643-6. doi: 10.1023/a:1011191720336. Ann Oncol. 2001. PMID: 11432622 Free article.

10

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhommé C. Pautier P, et al. Among authors: petit t. Gynecol Oncol. 2010 Feb;116(2):157-62. doi: 10.1016/j.ygyno.2009.10.076. Gynecol Oncol. 2010. PMID: 20109725 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters